Cellectis Prices IPO of American Depositary Shares at $41.50 Each
French gene-editing company Cellectis priced its initial public offering of 5.5 million American Depositary Shares (ADS) at $41.50 per share, with trading set to begin on the Nasdaq Global Market.
Paris, France – March 24, 2015 – Cellectis, a gene-editing company specializing in immuno-oncology, announced the pricing of its initial public offering (IPO) of American Depositary Shares (ADS). The company priced 5.5 million ADSs at $41.50 per ADS. Each ADS represents one ordinary share of Cellectis. The ADSs are scheduled to commence trading on the Nasdaq Global Market under the ticker symbol "CLLS" on Wednesday, March 25, 2015.
The offering includes an overallotment option granted to the underwriters, allowing them to purchase up to an additional 825,000 ADSs within 30 days. Cellectis focuses on developing and commercializing novel therapeutics in the field of immuno-oncology, utilizing its proprietary gene-editing technologies.
BofA Merrill Lynch, Jefferies, and Piper Jaffray & Co. are serving as the joint book-running managers for the offering. Oppenheimer & Co. and Trout Capital are acting as co-managers. This IPO marks a significant step for Cellectis as it aims to advance its pipeline of gene-edited cell therapies for cancer treatment.
The offering was made by means of a prospectus. Further details can be found on the U.S. Securities and Exchange Commission's EDGAR database. Cellectis' work in gene editing holds potential for developing next-generation treatments in a critical area of medicine.